PubMed Health⌕ Search

Biomedical subjects

W J Stuckey

Publications and source records attributed to W J Stuckey.

52 records · Page 3Linked to original sources
PubMedDate not supplied

Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.

Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks. Six of 58 patients achieved a complete remission. One complete remission and 1 partial remission were observed among 26 patients treated with the single pulse schedule. Five (16%) complete remissions were attained among 32 patients treated on the daily x 5 schedule. Responses were observed only in patients with non-lymphoblastic leukemia. DHAD was very well tolerated with myelosuppression as the major toxicity. Nausea and vomiting were minimal. Subclinical cardiac toxicity occurred in two patients. This was identified by serial reductions in cardiac ejection fractions. DHAD appears to have significant activity in acute non-lymphoblastic leukemia with minimal toxicity.

Acute Disease↗
PubMedDate not supplied

Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.

An abnormal fibrinogen (Fibrinogen New Orleans, or FNO) has been found in a 30 year-old woman, her mother and daughter, but not her father. The propositus suffered mild bleeding, but not thrombo-embolism or abnormal wound healing. Plasma and purified fibrinogen from the propositus caused a prolongation in the clotting time of normal plasma. FNO had increased anodal migration when studied by immunoelectrophoresis. We have been able to follow the release of fibrinopeptides A and B using sensitive SDS-PAGE. In FNO, release of the A peptide was markedly delayed, whereas the cleavage of B peptide was much less delayed, compared to that of A peptide.

Adult↗
PubMedDate not supplied

Racial differences in platelet survival time in patients with symptomatic coronary atherosclerosis.

Platelet survival times were studied in 40 patients (21 white and 19 black) with coronary artery disease and stable effort induced angina pectoris. The platelet survival times of 19 white controls (9.27 +/- 0.49 days; mean +/- SD) were not significantly different from those of 12 black controls (8.88 +/- 0.81 days), and the platelet survival times for 21 white patients with coronary artery disease (8.46 +/- 0.65 days) were lower than the times for both the white controls (p less than 0.01) and the combined control group (p less than 0.01). However, the difference between the mean platelet survival times of 19 black patients (9.22 +/- 0.68) and the control groups was not significant, and the difference between the mean platelet survival times of the 21 white patients and the 19 black patients was significant (p less than 0.01). Stepwise multiple linear regression analysis indicated that race was the most significant factor in predicting shortened platelet survival (r = 0.4783; p less than 0.01). It is concluded that racial background should be considered in the interpretation of platelet studies and that reported racial differences in the rate and extent of atherosclerotic lesions may be related to racial differences in platelet consumption.

Black People↗
PubMedDate not supplied

Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia.

The addition of a single monthy dose of daunorubicin (25 mg/m given intravenously) to the maximum tolerated dose of methotrexate (25 mg/m/dose given orally twice weekly) was evaluated as a maintenance regimen in 0 children with acute lymphoblastic leukemia. Seven patients who were nonevaluable were excluded from the study; 31 patients received methotrexate alone and 32 patients received a combination of methotrezate and daunorubicin. There was no significant difference between the distribution of remission times for the two maintenance regimens (medians of 147 and 162 days, respectively). For patients with only one previous remission, the median length of remission in this study was significantly shorter than that of the original remission time. Despite the known myelosuppressive effects of both agents, daunorubicin did not cause additional toxicity nor did it interfere with the scheduled methotrexate therapy. Although the addition of daunorubicin to methotrexate does not appear to be beneficial in the treatment of acute leukemia, this combination could be evaluated in other cancers in which both agents are known to be effective.

Child↗
PubMedDate not supplied

Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study.

The Southwest Oncology Group did a limited institutional pilot study of the combination of doxorubicin and ifosfamide in the treatment of previously treated adult patients with acute leukemia. Thirty-four patients received one or two courses of the combination. All patients had received prior chemotherapy and 32 had received prior anthracycline chemotherapy. Three patients died before their responses could be fully evaluated. Fourteen patients achieved complete remission (41%) and one patient achieved partial remission. The complete remission rate was 27% for patients with acute myeloblastic leukemia (myelomonoblastic leukemia, monoblastic leukemia, and erythroleukemia) and 89% for patients with acute lymphocytic and undifferentiated leukemia (ALL). Toxic effects included severe hematologic reactions in 33 of 34 patients, hematuria in six patients, altered sensorium in one patient, and congestive heart failure in one patient. The safety of the combination was established and toxic side effects of this therapy were tolerable. The 89% complete remission rate for previously treated patients with ALL suggests that the combination of doxorubicin and ifosfamide may be particularly effective in ALL.

Acute Disease↗